Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab mechanism-of-action study in COPD
2024-512007-39-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of itepekimab in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Sanofi. Primary endpoints: Change from baseline in itepekimab pharmacodynamic normalized enrichment score derived from former smokers in endobronchial biopsies in current smokers with COPD, Change from baseline in itepekimab pharmacodynamics normalized enrichment score derived from former smokers in bronchial brushings in current smokers with COPD and 1 more. Started May 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-512007-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512007-39-00.